National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 119, 108141
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Canada
- Sanofi
- Pfizer
This publication has 11 references indexed in Scilit:
- Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use DisorderJournal of Addiction Medicine, 2020
- Buprenorphine prescribing for opioid use disorder in medical practices: can office‐based out‐patient care address the opiate crisis in the United States?Addiction, 2019
- Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013JAMA Psychiatry, 2017
- Medication-Assisted Treatment for Substance use Disorders within a National Community Health Center Research NetworkSubstance Abuse, 2016
- Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient SettingsJAMA, 2014
- Comparison of behavioral treatment conditions in buprenorphine maintenanceAddiction, 2013
- A Randomized Trial of Cognitive Behavioral Therapy in Primary Care-based BuprenorphineThe American Journal of Medicine, 2013
- Management of Substance Use Disorders in Ambulatory Care in the United States, 2001-2009Archives of internal medicine (1960), 2012
- Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependenceCochrane Database of Systematic Reviews, 2011
- A Meta-Analytic Review of Psychosocial Interventions for Substance Use DisordersAmerican Journal of Psychiatry, 2008